MedPath

KATHY MILLER

πŸ‡¦πŸ‡ΊAustralia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:0
Completed:5

Trial Phases

3 Phases

Phase 1:3
Phase 2:3
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
3 (37.5%)
Phase 2
3 (37.5%)
Not Applicable
2 (25.0%)

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Phase 2
Recruiting
Conditions
Estrogen-receptor-low Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer
Interventions
Drug: SOC Chemotherapy
First Posted Date
2023-05-06
Last Posted Date
2025-10-14
Lead Sponsor
Kathy Miller
Target Recruit Count
168
Registration Number
NCT05846789
Locations
πŸ‡ΊπŸ‡Έ

Emory University, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana, United States

πŸ‡ΊπŸ‡Έ

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

and more 2 locations

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1
Completed
Conditions
Metastatic Breast Cancer
Hormone Receptor Positive Tumor
Triple Negative Breast Cancer
Interventions
First Posted Date
2019-10-22
Last Posted Date
2024-03-22
Lead Sponsor
Kathy Miller
Target Recruit Count
34
Registration Number
NCT04134884
Locations
πŸ‡ΊπŸ‡Έ

Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States

πŸ‡ΊπŸ‡Έ

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Phase 1
Completed
Conditions
Triple Negative Breast Cancer
Metastatic Breast Cancer
Interventions
First Posted Date
2017-08-09
Last Posted Date
2021-01-07
Lead Sponsor
Kathy Miller
Target Recruit Count
18
Registration Number
NCT03243331
Locations
πŸ‡ΊπŸ‡Έ

IU Simon Cancer Center, Indianapolis, Indiana, United States

Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy

Phase 2
Completed
Conditions
Cancer of the Breast
Interventions
First Posted Date
2015-11-03
Last Posted Date
2021-12-15
Lead Sponsor
Kathy Miller
Target Recruit Count
42
Registration Number
NCT02595372
Locations
πŸ‡ΊπŸ‡Έ

Georgetown University, Washington, District of Columbia, United States

πŸ‡ΊπŸ‡Έ

Washington Hospital, Washington, District of Columbia, United States

πŸ‡ΊπŸ‡Έ

Indiana University Health North Hospital, Carmel, Indiana, United States

and more 6 locations

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Phase 1
Terminated
Conditions
Hepatocellular Carcinoma
Liver Cancer
HCC
Interventions
Drug: MLN0128 (RP2D)
First Posted Date
2015-10-14
Last Posted Date
2022-07-26
Lead Sponsor
Kathy Miller
Target Recruit Count
11
Registration Number
NCT02575339
Locations
πŸ‡ΊπŸ‡Έ

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

πŸ‡ΊπŸ‡Έ

University of Illinois Cancer Center, Chicago, Illinois, United States

πŸ‡ΊπŸ‡Έ

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 3 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.